Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Teladoc Health, Inc.NYSE: TDOC

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $94.19M rose 104.9% year over year, ahead of the +6.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 18.1% from the prior quarter. Over 3 fiscal years it compounded at +20.0% a year.

Context

  • Depreciation & amortization amounted to 14.4% of revenue in FY2025, up 5.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +104.9% holds above the trailing-twelve-month pace of +6.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$94.19M+18.1% QoQ
Last fiscal yearDec 2025
$363.12M+51.0% YoY
LTMMar 2026
$233.19M+6.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+104.9%——
1 year+51.0%——
3-year CAGR+20.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
363.12M USD
Year-over-year change
+51.0%
4-year CAGR
+15.0%

Depreciation & Amortization vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.2% is the 7th highest of 11, against a peer median of +16.2%.
  • Depreciation & amortization amounts to 9.3% of revenue for TDOC, versus a peer median of 4.7%.
TDOC Competitors
Depreciation & Amortization for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$233.19M USD+6.2%+20.0%9.3%
OMCLOmnicell, Inc.LTM Mar 2026$83.36M USD-5.7%-4.4%6.8%
EVOEvotec SELTM Mar 2026€73.11M EUR+32.5%+4.7%9.8%
AZTAAzenta, Inc.LTM Sep 2026$56.52M USD-7.7%—9.1%
PHRPhreesia, Inc.LTM Apr 2026$34.65M USD+22.0%+3.0%7.0%
NVCRNovoCure LimitedLTM Mar 2026$18M USD+53.3%+17.4%2.7%
PGNYProgyny, Inc.LTM Jun 2026$7.22M USD+79.8%+45.7%0.6%
OMDAOmada HealthLTM Mar 2026$5.67M USD+13.1%+8.2%2.0%
SDGRSchrödinger, Inc.LTM Sep 2026$4.4M USD-30.7%+11.5%1.6%
IMNMImmunome, Inc.LTM Sep 2026$2.69M USD-3.0%+67.3%—
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
Peer median (excluding TDOC) —+16.2%+11.5%4.7%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.03B2.41B2.6B2.57B2.53B
Cost of Revenue650.26M743.99M760.03M751.27M771.59M
Gross Profit1.38B1.66B1.84B1.82B1.76B
Gross Margin68.0%69.1%70.8%70.8%69.5%
Research & Development311.88M333.63M348.52M307.27M277.92M
Selling, General & Admin1.11B1.3B1.37B1.35B1.09B
Operating Expenses1.65B15.32B2.09B2.84B2.02B
Depreciation & Amortization207.57M209.93M254.11M240.51M363.12M
EBITDA(31.42M)(7.54M)43.61M31.72M147.3M
EBITDA Margin-1.5%-0.3%1.7%1.2%5.8%
Operating Income(265.63M)(13.65B)(248.55M)(1.02B)(262.96M)
Operating Margin-13.1%-567.3%-9.6%-39.7%-10.4%
Interest Income776K12.67M46.78M57.07M36.77M
Interest Expense81.14M21.94M22.28M23.8M19.71M
Other Income / Expenses(119.03M)(10.13M)28.95M27.23M27.43M
Income Before Tax(384.66M)(13.66B)(219.61M)(993.65M)(235.53M)
Pre-Tax Margin-18.9%-567.7%-8.4%-38.7%-9.3%
Income Tax Expense44.14M(3.81M)760K7.59M(35.21M)
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Net Margin-21.1%-567.5%-8.5%-39.0%-7.9%
EPS (Basic)(2.73)(84.60)(1.36)(5.87)(1.14)
EPS (Diluted)(2.73)(84.60)(1.34)(5.87)(1.14)
Weighted Avg Shares156.94M161.46M162.17M170.56M176.22M
Weighted Avg Shares (Diluted)156.94M161.46M164.58M170.56M176.22M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.